Advertisement
Research
Understanding the molecular/cellular underpinnings of diffuse malignant peritoneal mesothelioma (DMPM), a fatal malignancy with limited therapeutic options, is of utmost importance for the fruitful management ...
Journal of Hematology & Oncology 2017 10:140
Published on: 17 July 2017
Research
Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is ...
Journal of Hematology & Oncology 2017 10:138
Published on: 11 July 2017
Research
Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1
Journal of Hematology & Oncology 2017 10:139
Published on: 11 July 2017
Research
The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in pat...
Journal of Hematology & Oncology 2017 10:137
Published on: 6 July 2017
Review
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1...
Journal of Hematology & Oncology 2017 10:136
Published on: 5 July 2017
Research
Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) has largely replaced unstimulated bone marrow (un-BM) for allografting because of accelerated engraftment, but with ...
Journal of Hematology & Oncology 2017 10:135
Published on: 4 July 2017
Research
This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who r...
Journal of Hematology & Oncology 2017 10:134
Published on: 4 July 2017
Review
The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. Indeed, the two proteins act as regulators ...
Journal of Hematology & Oncology 2017 10:133
Published on: 3 July 2017
Research
UBE2O is proposed as a ubiquitin-conjugating enzyme, but its function was largely unknown.
Journal of Hematology & Oncology 2017 10:132
Published on: 3 July 2017
Research
Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and re...
Journal of Hematology & Oncology 2017 10:131
Published on: 26 June 2017
Research
Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased av...
Journal of Hematology & Oncology 2017 10:130
Published on: 24 June 2017
Research
Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechan...
Journal of Hematology & Oncology 2017 10:129
Published on: 21 June 2017
Research
The feasibility of cord blood transplantation (CBT) in adults is limited by the relatively low number of hematopoietic stem/progenitor cells contained in one single CB unit. The infusion of two CB units from d...
Journal of Hematology & Oncology 2017 10:128
Published on: 21 June 2017
Research
Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic ag...
Journal of Hematology & Oncology 2017 10:127
Published on: 20 June 2017
Rapid communication
MDM2 and CDK4 are frequently co-amplified in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). We aimed to determine whether combined MDM2/CDK4 targeting is associated wi...
Journal of Hematology & Oncology 2017 10:123
Published on: 19 June 2017
Research
Brain metastasis (BM) is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Recent studies demonstrated that microRNA-330-3p (miR-330-3p) was involved in NSCLC brain metastasis...
Journal of Hematology & Oncology 2017 10:125
Published on: 19 June 2017
Research
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustio...
Journal of Hematology & Oncology 2017 10:124
Published on: 19 June 2017
Research
Lymphatic metastasis is one of the leading causes of death in patients with different types of cancer and is the main prognostic factor for the disease survival. The formation of new lymphatic vessels (lymphan...
Journal of Hematology & Oncology 2017 10:122
Published on: 19 June 2017
Research
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients...
Journal of Hematology & Oncology 2017 10:126
Published on: 19 June 2017
Review
Despite administration of novel therapies, multiple myeloma (MM) remains incurable with resistance to drugs leading to relapse in most patients. Thus, it is critical to understand the detailed mechanisms under...
Journal of Hematology & Oncology 2017 10:121
Published on: 17 June 2017
Research
Impaired T cell reconstitution remains a major deterrent in the field of bone marrow (BM) transplantation (BMT) due to pre-conditioning-induced damages inflicted to the thymi of recipient hosts. Given the prev...
Journal of Hematology & Oncology 2017 10:120
Published on: 14 June 2017
Research
Sickle cell disease (SCD) is a disorder of red blood cells (RBCs) expressing abnormal hemoglobin-S (HbS) due to genetic inheritance of homologous HbS gene. However, people with the sickle cell trait (SCT) carr...
Journal of Hematology & Oncology 2017 10:119
Published on: 13 June 2017
Research
In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter stud...
Journal of Hematology & Oncology 2017 10:117
Published on: 12 June 2017
Research
Abnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which make them very suitable targets for the development of therapeutic approach against rapidly dividing and aggress...
Journal of Hematology & Oncology 2017 10:118
Published on: 12 June 2017
Letter to the Editor
Patients with B cell lymphomas bearing MYC translocation combined with translocation involving other genes, such as BCL2, BCL3, or BCL6, defined as double-hit lymphoma (DHL), have a poor prognosis. Recent studies...
Journal of Hematology & Oncology 2017 10:116
Published on: 8 June 2017
